Article Versions Notes

Hsueh SC, Scerba MT, Tweedie D, Lecca D, Kim DS, Baig AM, Kim YK, Hwang I, Kim S, Selman WR, et al. Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury. Biomedicines. 2022; 10(10):2449. https://doi.org/10.3390/biomedicines10102449

Hsueh, Shih Chang, Michael T. Scerba, David Tweedie, Daniela Lecca, Dong Seok Kim, Abdul Mannan Baig, Yu Kyung Kim, Inho Hwang, Sun Kim, Warren R. Selman, and et al. 2022. "Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury" Biomedicines 10, no. 10: 2449. https://doi.org/10.3390/biomedicines10102449

Hsueh, S. C., Scerba, M. T., Tweedie, D., Lecca, D., Kim, D. S., Baig, A. M., Kim, Y. K., Hwang, I., Kim, S., Selman, W. R., Hoffer, B. J., & Greig, N. H. (2022). Activity of a Novel Anti-Inflammatory Agent F-3,6′-dithiopomalidomide as a Treatment for Traumatic Brain Injury. Biomedicines, 10(10), 2449. https://doi.org/10.3390/biomedicines10102449